Jupiter Topco LLC Makes New $1.54 Million Investment in Denali Therapeutics Inc. $DNLI

Key Points

• Jupiter Topco LLC acquired 60,028 Denali Therapeutics shares worth approximately $1.54 million during the second quarter. Institutional investors collectively own 92.92% of the company.
• Analyst sentiment remains largely positive, with 14 Buy ratings, two Holds and one Sell; the consensus rating is “Moderate Buy” with an average price target of $35.85.
• Denali shares opened at $22.28 after declining 2.3%, while the company reported a second-quarter loss of $0.68 per share—worse than the $0.51 consensus estimate—despite revenue exceeding expectations.

Jupiter Topco LLC purchased a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 60,028 shares of the company's stock, valued at approximately $1,544,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Denali Therapeutics during the second quarter worth $26,000. Headlands Technologies LLC purchased a new stake in Denali Therapeutics in the 2nd quarter valued at approximately $26,000. Global Retirement Partners LLC acquired a new position in Denali Therapeutics during the 2nd quarter worth approximately $28,000. Johnson Financial Group Inc. purchased a new position in shares of Denali Therapeutics during the 3rd quarter worth approximately $29,000. Finally, State of Wyoming purchased a new position in shares of Denali Therapeutics during the 2nd quarter worth approximately $29,000. Hedge funds and other institutional investors own 92.92% of the company's stock.

Insider Activity

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the transaction, the insider directly owned 281,763 shares in the company, valued at approximately $7,063,798.41. The trade was a 1.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 9.70% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on DNLI. Wall Street Zen lowered Denali Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. Sanford C. Bernstein reaffirmed a "hold" rating on shares of Denali Therapeutics in a report on Monday, June 22nd. Robert W. Baird set a $34.00 price target on Denali Therapeutics in a research note on Friday, August 7th. Finally, BTIG Research reiterated a "buy" rating and issued a $39.00 price objective on shares of Denali Therapeutics in a research report on Monday, May 11th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $35.85.

Denali Therapeutics Trading Down 2.3%

Denali Therapeutics stock opened at $22.28 on Friday. The stock has a 50-day moving average price of $24.44 and a 200 day moving average price of $21.83. Denali Therapeutics Inc. has a 52 week low of $12.58 and a 52 week high of $27.30. The stock has a market cap of $3.56 billion, a PE ratio of -7.85 and a beta of 1.01. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The business had revenue of $3.60 million for the quarter, compared to the consensus estimate of $2.15 million. During the same quarter in the prior year, the company earned ($0.72) earnings per share. Equities research analysts predict that Denali Therapeutics Inc. will post -2.67 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.